Cencora (NYSE:COR) Rating Lowered to Hold at Wall Street Zen

Cencora (NYSE:COR) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report released on Friday.

A number of other equities research analysts have also recently commented on the stock. TD Cowen increased their target price on shares of Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Evercore ISI set a $400.00 price objective on shares of Cencora and gave the company an “outperform” rating in a report on Thursday, November 6th. JPMorgan Chase & Co. boosted their target price on Cencora from $344.00 to $417.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. Weiss Ratings restated a “buy (b-)” rating on shares of Cencora in a research report on Tuesday. Finally, Robert W. Baird increased their price target on Cencora from $355.00 to $395.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. Nine investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Cencora presently has an average rating of “Moderate Buy” and an average price target of $371.09.

Cencora Price Performance

Shares of Cencora stock opened at $368.93 on Friday. The stock has a market capitalization of $71.53 billion, a P/E ratio of 37.96, a PEG ratio of 1.56 and a beta of 0.63. The business has a 50 day simple moving average of $335.71 and a two-hundred day simple moving average of $307.63. Cencora has a 12 month low of $223.92 and a 12 month high of $377.54. The company has a debt-to-equity ratio of 3.64, a current ratio of 0.90 and a quick ratio of 0.53.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, topping the consensus estimate of $3.79 by $0.05. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The firm had revenue of $83.73 billion during the quarter, compared to analysts’ expectations of $83.36 billion. During the same period in the previous year, the business earned $3.34 earnings per share. The firm’s revenue for the quarter was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, analysts predict that Cencora will post 15.37 EPS for the current fiscal year.

Insider Activity at Cencora

In related news, Chairman Steven H. Collis sold 31,350 shares of the stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the transaction, the chairman directly owned 305,913 shares in the company, valued at approximately $88,671,942.18. This represents a 9.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Robert P. Mauch sold 5,097 shares of Cencora stock in a transaction on Monday, October 20th. The shares were sold at an average price of $326.80, for a total value of $1,665,699.60. Following the completion of the sale, the chief executive officer owned 37,940 shares in the company, valued at $12,398,792. This represents a 11.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 46,640 shares of company stock valued at $14,099,338 over the last quarter. 10.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Cencora

A number of institutional investors have recently made changes to their positions in COR. Vestcor Inc lifted its holdings in shares of Cencora by 0.5% in the 3rd quarter. Vestcor Inc now owns 5,196 shares of the company’s stock worth $1,624,000 after acquiring an additional 28 shares during the last quarter. Cornerstone Wealth Group LLC raised its position in Cencora by 1.3% in the third quarter. Cornerstone Wealth Group LLC now owns 2,383 shares of the company’s stock valued at $745,000 after purchasing an additional 30 shares during the period. Security Financial Services INC. lifted its stake in Cencora by 2.6% during the third quarter. Security Financial Services INC. now owns 1,325 shares of the company’s stock worth $414,000 after purchasing an additional 33 shares in the last quarter. Vermillion & White Wealth Management Group LLC boosted its position in shares of Cencora by 31.4% during the third quarter. Vermillion & White Wealth Management Group LLC now owns 138 shares of the company’s stock worth $43,000 after buying an additional 33 shares during the period. Finally, Atlantic Edge Private Wealth Management LLC grew its stake in shares of Cencora by 70.0% in the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after buying an additional 35 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.